Fundraise / allotmentFiled on BSE ·
Gujarat Themis Biosyn approves issuance of Non-Convertible Debentures up to ₹585 Cr
Guj. Themis Bio. · Pharmaceuticals & Biotechnology
What the filing says
- Board approved private placement issuance of NCDs aggregating up to ₹585 Crores
- NCDs will not be listed on any stock exchange
- Further details like allotment date, maturity, interest rate, and security will be disclosed later
Original filing
Board Meeting Outcome for Outcome Of The Board Meeting Held On 10.09.2026
Read the filing on BSE (PDF) →Companies guiding to strong growth
Ranked by management's own guidance on revenue and margins — not by us.
Waaree Energies
Electrical Equipment
Revenue: Rank 1Margin: Rank 1
Sign up free to see all 6 →
See full rankingsRank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
More from Guj. Themis Bio.
- Acquisition / mergerGujarat Themis Biosyn Ltd. completes acquisition of MicroBiopharm Japan Co., Ltd.
- Fundraise / allotmentGujarat Themis Biosyn Ltd allots ₹585 crore NCDs via private placement on 16-09-2026
- Fundraise / allotmentGujarat Themis Biosyn Ltd announces Board meeting on September 10, 2026
Other fundraise / allotment filings this fortnight
- Fundraise / allotmentInox GreenInox Green Energy Services Ltd allotted 1.81 crore equity shares via QIP in Sept 2026
- Fundraise / allotmentInox GreenInox Green Energy Services completes Qualified Institutions Placement on Sept 29, 2026
- Fundraise / allotmentBharat Parenterals LtdBharat Parenterals Limited approves preferential allotment of 9.13 lakh equity shares
- Fundraise / allotmentAurum Proptech LtdAurum PropTech allots 1.98 crore equity shares to REA India on preferential basis
- Fundraise / allotmentAurum Proptech LtdAurum PropTech Limited allots 1.98 crore shares to REA India on preferential basis
- Fundraise / allotmentRepco Home FinRepco Home Finance approved raising ₹1500 Cr NCDs and ₹1000 Cr Commercial Paper
Summary written by Arthneeti from the company's filing with the stock exchange; check the original filing for full details. Arthneeti is a research and analytics platform, not a SEBI-registered investment adviser, and nothing here is a recommendation to buy or sell.